Share-Based Payments (Tables)

6 Months Ended

Jun. 30, 2024

The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
(In millions)	2024		2023		2024		2023
Research and development	$	27.3	$	27.9	$	54.7	$	59.2
Selling, general and administrative	45.6		48.4		89.6		98.5

Subtotal	72.9		76.3		144.3		157.7
Capitalized share-based compensation costs	(2.3)		(2.6)		(5.6)		(5.9)
Share-based compensation expense included in total cost and expense	70.6		73.7		138.7		151.8
Income tax effect	(13.4)		(13.3)		(26.3)		(28.0)
Share-based compensation expense included in net income attributable to Biogen Inc.	$	57.2	$	60.4	$	112.4	$	123.8

The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
(In millions)	2024		2023		2024		2023
Time-vested restricted stock units	$	58.3	$	59.9	$	115.6	$	121.6


Performance stock units settled in stock	11.7		9.8		22.2		19.3
Employee stock purchase plan	1.8		2.1		6.3		6.8
Performance stock units settled in cash	0.1		2.2		(2.0)		4.7
Stock options	0.9		1.0		1.8		1.8
Market stock units	0.1		1.3		0.4		3.5
Subtotal	72.9		76.3		144.3		157.7
Capitalized share-based compensation costs	(2.3)		(2.6)		(5.6)		(5.9)
Share-based compensation expense included in total cost and expense	$	70.6	$	73.7	$	138.7	$	151.8